CORXEL Acquires Worldwide (excluding Greater China) Rights to an Oral Small Molecule GLP-1 RA for the Treatment of Obesity and Diabetes
23 déc. 2024 08h01 HE
|
Corxel Pharmaceuticals
CORXEL expands its cardiometabolic pipeline into obesity and diabetes.
Hypophosphatasia Epidemiology Forecast Report 2034: Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan
18 déc. 2024 09h58 HE
|
Research and Markets
Dublin, Dec. 18, 2024 (GLOBE NEWSWIRE) -- The "Hypophosphatasia - Epidemiology Forecast-2034" report has been added to ResearchAndMarkets.com's offering. The "Hypophosphatasia - Epidemiology...
MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)
16 déc. 2024 06h05 HE
|
MannKind
MANNKIND ANNOUNCES SIX-MONTH RESULTS FROM PHASE 3 INHALE-1 PEDIATRIC DIABETES TRIAL UTILIZING INHALED INSULIN (AFREZZA®)
Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
12 déc. 2024 17h02 HE
|
Biomea Fusion, Inc.
In preclinical experiments, icovamenib enhanced beta cell function and responsiveness of human islets to GLP-1-based therapies. These effects were associated with an increase in the expression levels...
CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India
11 déc. 2024 06h00 HE
|
MannKind
CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India
India Diabetes Care Market Report 2024: Focus on Digital Health Solutions and Telemedicine, Personalized Medicine and Data Analytics
11 déc. 2024 04h11 HE
|
Research and Markets
Dublin, Dec. 11, 2024 (GLOBE NEWSWIRE) -- The "India Diabetes Care Market, By Region, Competition, Forecast and Opportunities, 2020-2030F" report has been added to ResearchAndMarkets.com's...
RenaissThera Closes Seed Funding to Drive AI-Powered Therapies for Cardio-Metabolic Diseases
10 déc. 2024 08h00 HE
|
RENAISSTHERA PRIVATE LIMITED
RenaissThera Closes Seed Funding to Drive AI-Powered Therapies for Cardio-Metabolic Diseases
RenaissThera Closes Seed Funding to Drive AI-Powered Therapies for Cardio-Metabolic Diseases
09 déc. 2024 22h30 HE
|
RENAISSTHERA PRIVATE LIMITED
RenaissThera Closes Seed Funding to Drive AI-Powered Therapies for Cardio-Metabolic Diseases
Type 1 Diabetes Epidemiology Forecast to 2033
04 déc. 2024 04h07 HE
|
Research and Markets
Dublin, Dec. 04, 2024 (GLOBE NEWSWIRE) -- The "Type 1 Diabetes: Epidemiology Forecast to 2033" report has been added to ResearchAndMarkets.com's offering.T1D, formally referred to as...
[Latest] Global Point of Care Glucose Testing Market Size/Share Worth USD 5,455.3 Million by 2033 at a 4.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
27 nov. 2024 01h30 HE
|
Custom Market Insights
Austin, TX, USA, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Point of Care Glucose Testing Market Size, Trends and Insights By Product (Accu...